Lenacapavir Hits HIV at a Second Stage, Lab Study Finds
Lenacapavir, the long-acting drug behind the twice-yearly HIV prevention shot, appears to work against HIV in more ways than scientists knew. A team of Japanese researchers reports that in lab experiments the drug also disrupts how new virus particles are built, producing oversized particles that cannot cause infection. Kumamoto University announced the findings on November 16. The study was published in the Proceedings of the National Academy of Sciences (PNAS).
This is basic lab science. It does not change how lenacapavir is used, prescribed or dosed. But it helps explain why the drug is so potent, and it may help guide the next generation of HIV medicines. Here is what the researchers found and what it does and doesn't mean if you're living with HIV, taking PrEP, or dating someone who is.
What lenacapavir is
Lenacapavir is a capsid inhibitor. The capsid is the protein shell that protects HIV's genetic material. In the US, lenacapavir is sold under two brand names:
- Yeztugo, a twice-yearly injection for HIV prevention (PrEP), approved by the FDA in June 2025.
- Sunlenca, used together with other HIV medicines to treat adults whose HIV is resistant to many other drugs.
Scientists already knew that lenacapavir blocks steps early in HIV's life cycle, after the virus enters a cell, by disrupting the capsid core. That interferes with reverse transcription (copying the virus's genetic material) and with getting that material into the cell's nucleus. The new study looked at the other end of the cycle: when infected cells assemble and release new virus particles.
What the new study found
The paper, by Wright Andrews Ofotsu Amesimeku and colleagues at Kumamoto University, Hamamatsu University School of Medicine and other Japanese institutions, reports that:
- Lenacapavir binds to an earlier form of the capsid protein. Besides the mature capsid, the drug latched onto its precursor, a protein called Gag that helps build new virus particles. Kazuaki Monde of Kumamoto University, who led the work with Yasumasa Iwatani of Hamamatsu University School of Medicine, called this "an important and unexpected finding."
- Particle assembly went wrong. With the drug present, Gag formed abnormal clusters at the cell surface, and cells released unusually large virus-like particles, more than 200 nanometers across. Typical HIV particles are around 100 to 130 nanometers.
- The giant particles could not cause infection. They could still fuse with and enter target cells, but defects after entry stopped the virus from replicating.
- The effect on release needed high drug levels. The authors write that suppressing the release of virus from cells "required relatively high LEN concentrations," and that one common lab test had overestimated this effect.
The researchers used mass photometry, a way to measure single particles, and electron microscopy to see the oversized particles. They say the insights could help design improved capsid-targeting drugs that act on the late stages of HIV's life cycle.
What this doesn't mean
- It was done in the lab, not in people. The experiments used cells and virus in laboratory conditions. They don't tell us anything new about how well lenacapavir protects or treats people. That evidence comes from clinical trials.
- It doesn't change dosing or who can use the drug. Nothing about Yeztugo or Sunlenca changes because of this study. Questions about your own PrEP or treatment belong with your clinician.
- It isn't a cure. No HIV medicine, including lenacapavir, removes HIV from the body. Treatment keeps the virus under control, and PrEP lowers the chance of getting HIV.
Why it matters if you're dating
For people who date while living with HIV, or who date someone who is, the big picture hasn't changed, and it's good. People with HIV who take treatment and keep an undetectable viral load don't transmit HIV through sex, the message known as Undetectable = Untransmittable (U=U). For HIV-negative partners, PrEP options now include daily pills and long-acting shots. Our coverage of how the twice-yearly PrEP shot kept more people on PrEP than daily pills, Yeztugo side effects and injection-site lumps and the first tentatively approved generic version of the shot explains more.
Studies like this one matter because a better understanding of how today's drugs work feeds into tomorrow's options, such as longer-lasting treatment. Researchers are testing several approaches, including antibody infusions every eight weeks. Keep in mind that PrEP and HIV treatment don't protect against other STIs, as we explain in what PrEP and DoxyPEP don't protect against, so regular STI testing still matters.
If you're looking for people who understand life with HIV, explore HIV dating on MeetPositives or read our HIV dating tips.
Sources
- Amesimeku WAO, et al. "Lenacapavir binding to immature Gag induces giant virions and causes protease-dependent inhibition of viral release." Proceedings of the National Academy of Sciences, 2026. doi:10.1073/pnas.2609634123
- Kumamoto University. "HIV drug lenacapavir found to disrupt virus formation, creating giant noninfectious particles." Via Medical Xpress, November 16, 2026.
This article is for general information only and is not medical advice. It does not create a doctor-patient relationship. Talk with a licensed health care provider about your own situation.
Share This Story, Choose Your Platform!
About the author
Staff Writer
Comments (0)
Ask A Question
Have A Question, Personal Story, Or Situation You'd Like Help With? Share It Here. The More Context You Include, The More Thoughtful And Useful Our Guidance Can Be.
Our Editorial Team (And Occasional Relationship Contributors) May Choose Selected Submissions To Answer In An Upcoming Blog Post. All Submissions Are Reviewed And Published Anonymously—We Will Never Include Identifying Details.
Important:
If Your Question Is About Your Account, Billing, Upgrades, Reports, Or Technical Issues, Please Contact Customer Care Through The Help Pages So We Can Assist You Faster.
Tips For A Better Answer (Optional):
- Your Age Range + What You're Looking For (Dating, Friendship, Support)
- What You've Tried So Far
- What You're Hoping Happens Next
- Any Boundaries Or Dealbreakers You Want Respected
Responses Shared Here Are For General Information Only And Aren't Medical, Legal, Or Mental-Health Advice.
We Can't Provide Real-Time Or One-On-One Support Through This Form.

